Nutriband Clarifies Executive Order Impact, Advances Abuse-Deterrent Fentanyl Patch Development

Nutriband Inc. (NASDAQ: NTRB) has responded to the Trump Administration's Executive Order designating illicit fentanyl and its core precursor chemicals as weapons of mass destruction, clarifying that this designation should not be conflated with FDA-approved prescription fentanyl therapies. The company emphasized that transdermal fentanyl patches are produced under rigorous regulatory oversight and remain medically necessary for certain severe chronic pain patients, distinguishing legitimate medical use from the illicit drug crisis.

The company acknowledged ongoing public health concerns surrounding transdermal fentanyl patch abuse and accidental pediatric exposure, noting these issues have prompted regulatory and medical community attention. In response to these challenges, Nutriband is partnering with Kindeva Drug Delivery to develop AVERSA™ FENTANYL, which combines Nutriband's proprietary AVERSA™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. This collaboration aims to create a product that deters abuse and reduces accidental exposure while maintaining therapeutic access for patients who require prescription fentanyl products for legitimate medical needs.

According to company statements, AVERSA™ FENTANYL could potentially become the first abuse-deterrent opioid patch to reach the market, representing a significant advancement in pain management safety. The technology behind this development, detailed on the company's website at https://www.nutriband.com, can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This approach addresses multiple safety concerns simultaneously while preserving medication access for appropriate patients.

The market potential for this innovation is substantial, with Nutriband projecting that AVERSA™ FENTANYL could reach peak annual U.S. sales between $80 million and $200 million. The company plans an initial focus on the U.S. market, with stated goals for broader availability in major global medical markets. This development comes at a critical time when regulatory agencies and healthcare providers are seeking solutions that balance pain management needs with abuse prevention measures.

The broader implications of this development extend beyond commercial considerations to public health policy and patient safety. As the opioid crisis continues to evolve, technologies that can reduce abuse while maintaining therapeutic options for legitimate patients represent an important middle ground in addressing complex medical and social challenges. The company's news and updates, available through their communications channels including https://ibn.fm/NTRB, highlight how pharmaceutical innovation can respond to both regulatory developments and public health needs.

This development represents a convergence of pharmaceutical technology, regulatory awareness, and market opportunity that could influence how controlled substances are delivered and monitored in medical settings. By addressing specific safety concerns associated with existing fentanyl patch formulations while maintaining therapeutic efficacy, the AVERSA™ FENTANYL development demonstrates how targeted innovation can create solutions that serve multiple stakeholders including patients, healthcare providers, regulators, and public health authorities.